Back to All

Issue of Share Options

3 July, 2020

Diaceutics PLC (AIM: DXRX), the diagnostic commercialisation company, announces the issue of share options over ordinary shares of 0.2p each in the Company (“Share Options”) on 30 June 2020, to certain members of the Company’s senior management team and other key staff. These share options have been issued pursuant to certain contractual share-based entitlements in place prior to the IPO and are governed by the rules of the Company’s Employee Share Option Plan (“ESOP”). Share Options were granted as follows:

NameNumber of Share Options grantedTotal no. of ordinary shares under option post grant% of existing issued share capital
Damian Thornton (COO and PDMR)4,200102,7040.12%
Jordan Clark (CTO and PDMR)4,20076,1140.09%
Susanne Munksted (CPO and PDMR)4,20070,6720.08%

A further 214,500 Share Options were granted to 51 employees, each of whom received 4,200 Share Options. The Share Options vest in full after three years following date of grant. The exercise price of the Share Options is 0.2p per share being the nominal value of the share. Following the grant the total number of share options outstanding granted to the Company’s Directors, senior management team and key employees is 1,790,762, representing approximately 2.13% of the Company’s current issued share capital of 84,068,923.

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014
1Details of the person discharging managerial responsibilities/person closely associated
a.NameDamian Thornton
2Reason for notification
a.Position/StatusChief Operating Officer
b.Initial notification/ AmendmentInitial
3Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a.NameDiaceutics PLC
b.LEI213800VEWQBB39ZB8J81
4Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.Description of the financial instrument, type of instrument Identification CodeOptions over new ordinary shares of 0.2p each   ISIN: GB00BJQTGV64
b.Nature of the transactionGrant of share options
c.Price(s) and volume(s)





Price(s)Volume(s)
Exercise price of 0.2p per share4,200

e.Date of the transaction30 June 2020
f.Place of the transactionOutside a trading venue

 

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014
1Details of the person discharging managerial responsibilities/person closely associated
a.NameJordan Clark
2Reason for notification
a.Position/StatusChief Technology Officer
b.Initial notification/ AmendmentInitial
3Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a.NameDiaceutics PLC
b.LEI213800VEWQBB39ZB8J81
4Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.Description of the financial instrument, type of instrument Identification CodeOptions over new ordinary shares of 0.2p each   ISIN: GB00BJQTGV64
b.Nature of the transactionGrant of share options
c.Price(s) and volume(s)





Price(s)Volume(s)
Exercise price of 0.2p per share4,200

e.Date of the transaction30 June 2020
f.Place of the transactionOutside a trading venue

 

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014
1Details of the person discharging managerial responsibilities/person closely associated
a.NameSusanne Munksted
2Reason for notification
a.Position/StatusChief Precision Officer
b.Initial notification/ AmendmentInitial
3Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a.NameDiaceutics PLC
b.LEI213800VEWQBB39ZB8J81
4Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.Description of the financial instrument, type of instrument Identification CodeOptions over new ordinary shares of 0.2p each   ISIN: GB00BJQTGV64
b.Nature of the transactionGrant of share options
c.Price(s) and volume(s)





Price(s)Volume(s)
Exercise price of 0.2p per share4,200

e.Date of the transaction30 June 2020
f.Place of the transactionOutside a trading venue

About Diaceutics

At Diaceutics we believe that every patient should get the precision medicine they deserve. We are a data analytics and end-to-end services provider enabled by DXRX - the world’s first Network solution for the development and commercialization of precision medicine diagnostics. 

Diaceutics has worked on every precision medicine brought to market and provides services to 36 of the world’s leading pharmaceutical companies. We have built the world’s largest repository of diagnostic testing data with a growing network of 2500 labs in 51 countries.